Press Release: Achaogen : Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
-- ZEMDRI's once-daily 30-minute infusion facilitating usage in the outpatient setting ---- Company's recent restructuring aimed at conserving capital to continue assessment of strategic alternatives --
Read full article »
Achaogen develops and commercializes novel antibacterials to treat the multi-drug resistant gram-negative infections.
Read more